原发性皮肤T细胞淋巴瘤
Primary cutaneous T-cell lymphoma
基本事实
- 患病率
- 1-9 / 100 000（Europe）
相关基因 2来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来，「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| HAVCR2 | hepatitis A virus cellular receptor 2 | ORPHA:86884 |
| TNFRSF1B | TNF receptor superfamily member 1B | ORPHA:2584 |
近两年的全球研究 103L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-07A digital polymerase chain reaction method targeting non-recombined T-cell receptor sequences aids in diagnosing primary cutaneous T-cell lymphomas
- 2026-06开放获取Mycosis Fungoides with Concurrent Squamous Cell Carcinoma in a Young Patient: A Rare Case
- 2026-06Rare case of CD20-positive primary cutaneous T-cell lymphoma, NOS, with an aggressive clinical course
- 2026-06开放获取Granulomatous cutaneous T-cell lymphoma in a patient with atage IVB of mycosis fungoides: a case report and literature review
- 2026-05开放获取Dose-de-escalated focal radiotherapy for primary cutaneous T-cell lymphoma: a lesion-based retrospective cohort study
- 2026-05开放获取Peripheral T-Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long-Term Outcomes
- 2026-05开放获取Development and validation of a prognostic nomogram for overall survival in patients with primary cutaneous T-cell lymphoma: A SEER-based study
- 2026-04病例报告Chidamide maintenance after allogeneic hematopoietic stem cell transplantation in mycosis fungoides: A case report
- 2026-04综述Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): A practical compartment-based review
- 2026-04开放获取Age-related histopathological and immunophenotypic variations in early-stage mycosis fungoides: a multicentre retrospective study in Türkiye
- 2026-04Hypopigmented CD8 + Mycosis Fungoides in Sri Lanka: Clinicopathologic Evidence for an Indolent Variant
- 2026-04病例报告开放获取Mycosis Fungoides With Large Cell Lymphoma Transformation: A Report of a Rare Case
- 2026-04Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor<sup>®</sup> (Mechlorethamine) in the Treatment of CTCL
- 2026-04开放获取Molecular Markers Distinguishing Early-Stage Mycosis Fungoides From Atopic Dermatitis Skin Lesions
- 2026-03综述开放获取Mimicry in Cutaneous Malignancy-Rare Forms of Mycosis Fungoides as Diagnostic Pitfalls: A Narrative Review
- 2026-03开放获取ZNF460 inhibits HMGCL and promotes PI3K pathway in colon cancer
- 2026-03开放获取Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part II: reverse transcriptase-polymerase chain reaction
- 2026-03开放获取Prognostic factors in Sézary syndrome - a retrospective propensity score-matched study on 1277 patients
- 2026-03病例报告开放获取Moderate-Dose Local Radiotherapy in Symptomatic CD30-Positive, Anaplastic Lymphoma Kinase (ALK)-Negative Primary Cutaneous T-cell Lymphoma
- 2026-03开放获取Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part 1
境外已获批用于本病的药物 4L2
欧盟 2 项、美国 2 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Ledaga欧盟2017-03-03chlormethine官方记录
- Poteligeo欧盟2018-11-22mogamulizumab官方记录
- Valchlor美国2013-08-23meclorethamine官方记录
- Adcetris美国2017-11-09brentuximab vedotin官方记录
已获孤儿药资格、尚未获批的在研药物（5 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Methotrexate with laurocapram美国1990-10-15Topical treatment of mycosis fungoides.官方记录
- human anti-CD4 monoclonal antibody美国2004-08-13Treatment of mycosis fungoides官方记录
- naloxone美国2010-11-23Topical treatment of pruritus associated with mycosis fungoides官方记录
- MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p美国2017-03-30Treatment of mycosis fungoides官方记录
- priliximab美国2017-09-18Treatment of mycosis fungoides (MF)官方记录
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 19L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 10
- 招募中NCT02848274ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome中国研究中心 1 个：Beijing
- 招募中NCT05518851TreAtments and outComes in paTients With prImary CutAneous Lymphoma中国研究中心 5 个：Beijing、Guandong、Jinan、Nanjing
- 招募中NCT06436677A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma中国研究中心 3 个：Beijing
- 招募中NCT06716658JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas中国研究中心 2 个：Tianjin
- 招募中NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies中国研究中心 1 个：Tianjin
- 招募中NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas中国研究中心 4 个：Beijing、Shanghai、Zhanjiang
- 招募中NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas中国研究中心 3 个：Beijing、Shanghai
- 招募中NCT07754890Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma中国研究中心 1 个：Beijing
- 尚未开始招募NCT07535710Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma中国研究中心 2 个：Shanghai、Wuxi
- 尚未开始招募NCT07717580Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)中国研究中心 1 个：Beijing
其他状态的试验（9 项）
- 已终止NCT02597153Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas中国研究中心 1 个：Beijing
- 已完成NCT03493451Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms中国研究中心 13 个：Beijing、Chengdu、Fuzhou、Guangzhou、Hangzhou、Harbin 等 10 地
- 状态未知NCT03999697A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies中国研究中心 1 个：Hefei
- 状态未知NCT04296786Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study中国研究中心 1 个：Beijing
- 状态未知NCT05781386A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors中国研究中心 1 个：Guanzhou
- 已完成NCT05442554A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma中国研究中心 4 个：Beijing、Chengdu、Shanghai
- 进行中·不再招募NCT06285370A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy中国研究中心 8 个：Beijing、Chengdu、Guangzhou、Hangzhou、Henan、Hohhot 等 8 地
- 状态未知NCT06037239Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study中国研究中心 1 个：Beijing
- 进行中·不再招募NCT06485219A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma中国研究中心 2 个：Chengdu、Shanghai
中国境外的在招试验 81L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国51意大利9西班牙5法国5澳大利亚3丹麦2韩国2德国2Costa Rica1比利时1荷兰1Moldova1波兰1罗马尼亚1另有 6 个国家/地区
CT.gov 报告命中 81 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07608549FLASH Pilot Phase 1 Safety Study
- 尚未开始招募NCT07691450Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma美国
- 尚未开始招募NCT05728879Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution美国
- 尚未开始招募NCT07714187A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides美国
- 尚未开始招募NCT07710781Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
- 尚未开始招募NCT07682792Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia美国
- 尚未开始招募NCT07192471A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma意大利、西班牙、美国
- 尚未开始招募NCT07529405A Study of VG712 in Patients With Mycosis Fungoides美国
- 尚未开始招募NCT07658924Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma
- 尚未开始招募NCT07538960Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.Costa Rica
- 尚未开始招募NCT07477769Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
- 招募中NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies美国
- 招募中NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma美国
- 招募中NCT07195916A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies澳大利亚、比利时、丹麦、意大利、美国
- 尚未开始招募NCT07213882A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）